- Meridian Bioscience Inc's VIVO subsidiary Magellan Diagnostics Inc has expanded the Class I recall of its LeadCare Test Kits used to detect lead in whole blood.
- Magellan provides two controls in the test kits designed to mimic blood and are spiked with lead to specific target values with an associated acceptable range.
- Results of the control tests within the acceptable range indicate that the system is operating properly before testing patient samples.
- In May 2021, Magellan initiated this voluntary recall after identifying an ongoing issue with testing of the controls included in the LeadCare Test Kits.
- Magellan received reports that control tests of either the "Low-Control" and/or the "High-Control" generated a "low" result.
- Impacted LeadCare Test Kits lots could potentially underestimate blood lead levels when processing patient blood samples.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: VIVO stock closed 1.73% higher at $20.59 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in